# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k112430   
B. Purpose for Submission: Minor labeling modification to a previously cleared device (k9   
C. Measurand: Lactic acid   
D. Type of Test: Quantitative, electrochemical biosensor (lactate oxidase)   
E. Applicant: Abbott Point of Care Inc.   
F. Proprietary and Established Names: i-STAT Lactate Test

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1450, Lactic acid test system

2. Classification: Class I, meets limitations of exemptions per 21 CFR 862.9 (c)(9)

3. Product code: KHP â€“ Acid, Lactic, Enzyme Method

4. Panel: Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): : See indications for use below

2. Indication(s) for use:

The Lactate Acid Test is indicated for (1) the diagnosis and treatment of lactic acidosis in conjunction with measurements of blood acid/base status, (2) monitoring tissue hypoxia and strenuous physical exertion, and (3) diagnosis of hyperlactatemia.

The Lactate Test, as part of the i-STAT System, is intended for the in vitro measurement of lactate in arterial, venous, or capillary whole blood.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: i-STAT analyzer

I. Device Description: Refer to k982071

# J. Substantial Equivalence Information:

1. Predicate device name(s): iSTAT Lactate test

2. Predicate 510(k) number(s): k982071

3. Comparison with predicate:

No changes were made to the device since k982071. Only minor labeling changes were made to the labeling in this submission.

# K. Standard/Guidance Document Referenced (if applicable):

No standards were referenced in the submission

# L. Test Principle:

Lactate is measured amperometrically by conversion of lactate to pyruvate and hydrogen peroxide by lactate oxidase immobilized on a biosensor.

No changes have been made to the device technology in this submission. Refer to k982071

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility : Established in the original submission (k982071) b. Linearity/assay reportable range: Established in the original submission (k982071) c. Traceability, Stability, Expected values (controls, calibrators, or methods): Established in the original submission (k982071) d. Detection limit: Established in the original submission (k982071) e. Analytical specificity: Established in the original submission (k982071) f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device: Established in the original submission (k982071)   
b. Matrix comparison: Established in the original submission (k982071)

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

$b$ . Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range: Established in the original submission (k982071)

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.